Vectura

What Vectura does

Vectura Group Ltd. is a UK-headquartered pharmaceutical contract development and manufacturing organization (CDMO) specializing in inhalation drug delivery. Founded in 1997 in Chippenham, the company historically operated as a publicly traded entity on the London Stock Exchange (ticker: VEC) before being acquired by Molex, via its Phillips Medisize subsidiary (itself backed by Koch Industries), in January 2025 and converted into a private operating subsidiary. Vectura's product and service offering spans pressurized metered-dose inhalers (pMDI), dry powder inhalers (DPI) including the AirFluSal GyroHaler platform, nasal spray devices, and nebulization systems such as the FOX Vibrating Mesh Nebulizer. Following integration with Phillips Medisize, the device portfolio has extended into parenteral delivery through the Aria Smart Autoinjector and Envoi Pen Injector platforms.

The company's business model is B2B contract development, licensing, and manufacturing: Vectura develops proprietary device and formulation platforms on behalf of pharmaceutical partners, supports regulatory submissions, and supplies commercial-scale manufacturing, generating revenue through development milestones, licensing royalties, and per-unit manufacturing fees. The company supports 13 commercially launched inhaled medicines delivered through its partners and treats roughly 10 million patients worldwide (2020). Named major pharma partners include Novartis, GSK, Bayer, Sandoz, Mundipharma, Hikma, and Kyorin, with primary end indications in asthma and COPD.

Vectura's operating footprint is anchored in the United Kingdom and Ireland with device development centers and a manufacturing campus, complemented by the GoCo Health Innovation City site in Sweden, where the company has moved to acquire full ownership of the campus. Headcount sits in the 251–500 employee range. Historical M&A — Innovata (2006), Activaero (2014), and SkyePharma (2016) — built the current inhalation stack, and the 2025 acquisition by Phillips Medisize repositions Vectura inside a global CDMO group with pharmaceutical, medical device, and combination product capabilities.

Name

Vectura

Legal name

Vectura Group Ltd.

Website

https://vectura.com

Company type

Private

Founded year

1997

Operating status

Acquired

Headcount range

251–500 employees

Short description

Vectura is a UK-headquartered inhalation drug delivery CDMO, formerly publicly traded on the LSE, now a private Phillips Medisize subsidiary. It develops and supplies pMDI, DPI, nebulizer, and nasal device platforms plus autoinjectors for major pharma partners including Novartis, GSK, and Bayer in asthma and COPD.

Ownership category

akta.pro rank

Product category

Inhalation Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Inhalers (MDI/DPI/SMI) (HLAHAIAI)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Inhalation drug delivery
• Pharmaceutical CDMO services
• Dry powder inhalers
• Nebulizer technology
• Respiratory drug formulation

Headquarters

HQ city

Chippenham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: CDMO providing pharmaceutical development and manufacturing services for inhalation therapies. Services include formulation, device development, clinical trial production, and commercial supply for pharmaceutical partners developing inhaled medicines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Vectura is a contract development and manufacturing organization (CDMO) specializing in inhalation and nasal drug delivery for pharmaceutical partners. The company provides customizable inhaler platform products (Dry Powder Inhalers, Metered Dose Inhalers, and the FOX Vibrating Mesh Nebulizer) along with end-to-end formulation science, device engineering, pharmaceutical analysis, clinical trial production, and commercial manufacturing services for pMDI, DPI, nasal inhaler, and nebulization devices targeting small molecules, biologics, complex combinations, and generic products.

Product overview

Vectura (now part of Phillips Medisize, a Molex company) operates as an inhalation and nasal drug delivery CDMO offering a comprehensive platform of customizable inhaler products and development services. The portfolio includes Dry Powder Inhalers (DPI) based on the commercially validated AirFluSal GyroHaler platform, Metered Dose Inhalers (pMDI), and the FOX Vibrating Mesh Nebulizer for liquid drug nebulization. These platform products are complemented by smart injection devices (Aria Smart Autoinjector, Envoi Pen Injector). The company provides end-to-end services spanning inhalation product development, formulation expertise, pharmaceutical analysis, bespoke device design, and clinical trial production. Vectura's formulation science and device technology contributed to 13 inhaled medicines launched by partners including GSK, Novartis, Bayer, Sandoz, Mundipharma, and Hikma, used by 10 million patients worldwide in 2020. The 2025 acquisition expanded capabilities to include small molecules, biologics, complex combinations, and generic products for pMDI, DPI, nasal inhaler, and nebulization devices.

Differentiator

Problem solved

Functional benefit

Brands

• FOX Vibrating Mesh Nebulizer: A compact, handheld, breath-activated, battery-powered inhalation system that uses vibrating-mesh technology to deliver nebulized liquid drugs with high, consistent performance.

Products and services

• Dry Powder Inhalers (DPI) Platform Customizable dry powder inhaler platform building on the commercially validated AirFluSal GyroHaler platform, offering various user interfaces and payload volumes with proven regulatory track record. Licensed to and developed for pharmaceutical partners for pulmonary drug delivery.
• FOX Vibrating Mesh Nebulizer
• Metered Dose Inhalers (pMDI) Platform
• Inhalation Product Development Services
• Inhalation Formulation Services
• Inhalation Pharmaceutical Analysis Services
• Bespoke Inhalation Device Design
• Inhalation Clinical Trial Production and Supply

Quantifiable outcome

• 10 million patients worldwide used products developed with Vectura technology in 2020
• +1 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Molex Inc. (Phillips-Medisize subsidiary)coreStrategic or Co-development Partner · 1 January 2025Molex Inc., through its Phillips-Medisize subsidiary, acquired UK-based Vectura Group Ltd. in January 2025 to expand capabilities in inhalation and respiratory therapies. The acquisition strengthened Molex's healthcare portfolio with advanced inhalation and drug-delivery technologies, adding formulation science, device technology, and 25+ years of inhaled development expertise.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Lonza Group: Global CDMO leader offering services across small molecules, biologics, and drug product development including inhalation-related capabilities. Provides broad-incumbent competition with deep manufacturing scale and similar end-customers.
• West Pharmaceutical Services: Global drug delivery and containment solutions provider with expanding inhalation and respiratory device capabilities in addition to its core injectable components business. Broad-incumbent peer with overlapping pharma customer base.
• Recipharm: European CDMO providing inhalation and sterile manufacturing services, including formulation for respiratory products. Adjacent competitor with overlapping inhalation offering as part of a broader pharmaceutical contract manufacturing portfolio.
• Catalent: Large-scale, multi-modality CDMO with established inhalation and respiratory capabilities alongside biologics, oral, and sterile fill-finish. Operates as a broad incumbent offering many of the same inhalation CDMO services as Vectura across a much larger portfolio.

Direct peers

• Hovione: Portugal-headquartered CDMO with deep inhalation and respiratory drug development capabilities, including particle engineering, formulation, and device services. Directly competes with Vectura on inhaled formulation and manufacturing for pharma partners.
• 3M Drug Delivery Systems: Division of 3M specializing in inhalation and transdermal drug delivery devices, including DPIs and metering technologies. Directly comparable to Vectura's device platform business for pharma partners developing inhaled products.
• Aptar Pharma: Global drug delivery device manufacturer with a strong portfolio of pMDI, DPI, nasal spray, and elastomeric closures serving inhalation and injectable applications. Overlaps directly with Vectura's platform devices (DPI, pMDI, nasal) and works with the same major pharma partners.
• Nemera: Drug delivery device company offering a portfolio of inhalers, nasal, and ophthalmic devices with development and manufacturing services. Competes with Vectura at the device platform tier of the inhalation value chain.

Regional players

• Cobra Biologics (part of Charles River Laboratories): Biologics-focused CDMO serving gene therapy, viral vector, and biologic drug substance needs with European manufacturing footprint. Adjacent competitor where Vectura's emerging biologics-in-inhaled offering intersects with broader biologics CDMO demand.

Emerging players

• Iconovo: Swedish inhalation CDMO developing proprietary DPI platforms and offering formulation services for pharma partners. Smaller, emerging competitor operating in the same niche as Vectura with comparable inhalation-only focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/PhillipsPlasticsCorp
• Xx.com/vecturagroup
• LinkedInlinkedin.com/company/vectura

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vectura